Citius Pharmaceuticals Inc Stock Price, News & Analysis

Citius Oncology (NASDAQ:CTOR) has announced a $9.0 million registered direct offering and concurrent private placement. The company will issue 5,142,858 shares of common stock at a combined effective price of $1.75 per share to a single institutional investor.

The deal includes unregistered warrants to purchase an additional 5,142,858 shares at an exercise price of $1.84 per share. These warrants will be exercisable after six months and expire 5.5 years from issuance. The offering is expected to close around September 10, 2025, with Maxim Group LLC serving as the sole placement agent.

Citius Oncology (NASDAQ:CTOR) has announced the deployment of a proprietary AI platform to enhance its commercial team's performance ahead of the anticipated LYMPHIR™ launch for cutaneous T-cell lymphoma (CTCL) treatment. The platform leverages advanced data analytics and machine learning to identify potential LYMPHIR candidates and optimize healthcare provider engagement.

The AI system analyzes treatment patterns and diagnosis data to support targeted prescriber outreach. It features a continuous learning model that integrates real-world U.S. claims data and marketing performance analytics to deliver predictive insights and enable personalized customer engagement across digital and in-person channels.

Citius Pharmaceuticals (NASDAQ:CTXR) reported its fiscal Q3 2025 results and provided updates on its transition to a commercial organization. The company secured $12.5 million in gross financings during Q3, with an additional $9 million raised by Citius Oncology in July 2025.

Key financial metrics include a net loss of $9.2 million ($0.80 per share), reduced from $10.6 million in Q3 2024. R&D expenses decreased to $1.6 million from $2.8 million year-over-year, while G&A expenses declined to $4.4 million from $4.8 million. The company ended the quarter with $6.1 million in cash.

Citius is preparing for the U.S. launch of LYMPHIR™ in Q4 2025 for cutaneous T-cell lymphoma treatment, having completed commercial-scale manufacturing, labeling, packaging, and distribution agreements.

Citius Oncology (NASDAQ:CTOR) has successfully closed its public offering, raising approximately $9.0 million in gross proceeds. The offering consisted of 6,818,182 shares of common stock and warrants at a public offering price of $1.32 per share.

The warrants are immediately exercisable at $1.32 per share and will expire in five years. The company plans to use the proceeds primarily to support the commercialization of LYMPHIR, including milestone and royalty payments, as well as for working capital and general corporate purposes. Maxim Group LLC served as the sole placement agent for this "reasonable best-efforts" offering.

Citius Oncology (NASDAQ:CTOR) has announced the pricing of a public offering to raise $9.0 million through the sale of 6,818,182 shares of common stock and warrants at $1.32 per share. The warrants will have the same exercise price, be immediately exercisable, and expire in five years.

The company plans to use the proceeds primarily for the commercialization of LYMPHIR, including milestone and royalty payments, as well as working capital. The offering, managed by Maxim Group LLC as sole placement agent, is expected to close around July 17, 2025.

Citius Oncology (NASDAQ:CTOR) has signed a distribution services agreement with Cencora (formerly AmerisourceBergen) for its FDA-approved immunotherapy LYMPHIR™. The agreement enhances the company's commercial infrastructure for the distribution of LYMPHIR, which treats relapsed or refractory cutaneous T-cell lymphoma (CTCL).

This partnership expands Citius Oncology's distribution network and complements a previously announced distribution agreement, strengthening the company's market reach and supporting long-term scalability. Under the agreement, Cencora will serve as a wholesale distributor for LYMPHIR, facilitating product availability across its distribution network.

Citius Pharmaceuticals (NASDAQ:CTXR) has successfully regained compliance with Nasdaq's minimum bid price requirement. The company maintained a closing bid price of $1.00 or higher for 10 consecutive trading days from June 20, 2025 to July 3, 2025, meeting Nasdaq Listing Rule 5550(a)(2).

As a result, the previously scheduled Nasdaq Hearing Panel has been cancelled, and CTXR will continue to be listed and traded on the Nasdaq Stock Market. CEO Leonard Mazur emphasized the company's commitment to developing critical care products and creating shareholder value.

Citius Oncology (NASDAQ: CTOR) is preparing for the commercial launch of LYMPHIR™, an FDA-approved immunotherapy for treating adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL), scheduled for the second half of 2025. The company has completed key launch preparations including commercial-scale manufacturing with 60-month shelf life inventory sufficient for 12-18 months post-launch. Distribution agreements with global logistics partners are being finalized to ensure broad U.S. access. The company has garnered significant interest from the medical community, with 70 institutional oncology centers already registered. LYMPHIR has secured NCCN guideline inclusion and a permanent J-code, positioning it well for reimbursement. The recent capital raise by parent company Citius Pharma (NASDAQ: CTXR) supports the launch, while strategic partnership discussions are ongoing to expand market reach.

Citius Pharmaceuticals (NASDAQ: CTXR) has closed its registered direct offering priced at-the-market, raising $6 million through the sale of 4,920,000 shares of common stock (or pre-funded warrants) at $1.22 per share. The offering includes short-term warrants to purchase up to 9,840,000 additional shares at $1.00 per share, potentially generating an additional $9.8 million if fully exercised within 24 months. H.C. Wainwright & Co. served as the exclusive placement agent. The company plans to use the proceeds to support the commercial launch of LYMPHIR™ and for general corporate purposes. The offering was made under a shelf registration statement filed with the SEC.